News

Mifepristone Still Showing Positive Results for Treatment of Central Serous Chorioretinopathy

For the past 18 years, reports have been published here on the slow progress of research for treatment of central serous chorioretinopathy (CSC). Sometimes misdiagnosed as early-onset age-related macular degeneration, CSC is a disease of the central retina (the macula) affecting mostly middle-aged males, and it is thought to be caused by over-production of stress [Read More]

Let's All Go to the Movies!

As of June 2, 2018, the law requires that audio description for the blind and visually impaired be made available by all digital first-run movie theaters. Almost all applicable theaters have complied, and others are in the process of converting to digital and upgrading to include description equipment. The Federal Government defines audio description as [Read More]

Abicipar for Wet AMD May Extend Time Between Treatments

Allergan and Molecular Partners have announced the release of two positive clinical trials of a new treatment for wet age-related macular degeneration (wAMD). The trials, named SEQUOIA and CEDAR, demonstrated that the biological drug Abicipar is equal to Genentech’s Lucentis (ranibizumab), with the added benefit that Abicipar treatments are effective at up to 12-week dosages. [Read More]